Elicio Therapeutics Files 8-K
Ticker: ELTX · Form: 8-K · Filed: Dec 3, 2024 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | Dec 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, financials
TL;DR
Elicio Therapeutics filed an 8-K on Dec 3rd, reporting other events and financials. Formerly Angion Biomedica.
AI Summary
Elicio Therapeutics, Inc. filed an 8-K on December 3, 2024, to report other events and financial statements. The company, formerly known as Angion Biomedica Corp. until February 28, 2014, is incorporated in Delaware and operates in the pharmaceutical preparations industry.
Why It Matters
This filing serves as an official notification of significant corporate events and financial reporting for Elicio Therapeutics, Inc., providing transparency to investors and the public.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not inherently present new risks.
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — Registrant
- Angion Biomedica Corp. (company) — Former company name
- December 3, 2024 (date) — Date of report
- February 28, 2014 (date) — Date of name change
- 001-39990 (other) — Commission File Number
- 11-3430072 (other) — IRS Employer Identification No.
- 451 D Street, 5th Floor Boston, Massachusetts 02210 (address) — Principal executive offices
- (857) 209-0050 (phone) — Registrant's telephone number
FAQ
What is the primary purpose of this Form 8-K filing for Elicio Therapeutics, Inc.?
The Form 8-K is filed to report 'Other Events' and 'Financial Statements and Exhibits' as of December 3, 2024.
When did Elicio Therapeutics, Inc. change its name from Angion Biomedica Corp.?
The company's name was changed from Angion Biomedica Corp. on February 28, 2014.
What is the Commission File Number for Elicio Therapeutics, Inc.?
The Commission File Number for Elicio Therapeutics, Inc. is 001-39990.
Where are Elicio Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 451 D Street, 5th Floor, Boston, Massachusetts 02210.
What is the IRS Employer Identification Number for Elicio Therapeutics, Inc.?
The IRS Employer Identification Number for Elicio Therapeutics, Inc. is 11-3430072.
Filing Stats: 433 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2024-12-03 07:10:52
Key Financial Figures
- $0.01 — ge on which registered) Common Stock, $0.01 par value per share ELTX The Nasdaq
Filing Documents
- d858884d8k.htm (8-K) — 24KB
- d858884dex991.htm (EX-99.1) — 16KB
- g858884g1203041425224.jpg (GRAPHIC) — 4KB
- 0001193125-24-269400.txt ( ) — 175KB
- eltx-20241203.xsd (EX-101.SCH) — 3KB
- eltx-20241203_lab.xml (EX-101.LAB) — 18KB
- eltx-20241203_pre.xml (EX-101.PRE) — 11KB
- d858884d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release dated December 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. By: /s/ ROBERT CONNELLY Date: December 3, 2024 Robert Connelly President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)